1. Home
  2. GMED vs GRFS Comparison

GMED vs GRFS Comparison

Compare GMED & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GMED
  • GRFS
  • Stock Information
  • Founded
  • GMED 2003
  • GRFS 1940
  • Country
  • GMED United States
  • GRFS Spain
  • Employees
  • GMED N/A
  • GRFS N/A
  • Industry
  • GMED Medical/Dental Instruments
  • GRFS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GMED Health Care
  • GRFS Health Care
  • Exchange
  • GMED Nasdaq
  • GRFS Nasdaq
  • Market Cap
  • GMED 7.2B
  • GRFS 7.2B
  • IPO Year
  • GMED 2012
  • GRFS 2006
  • Fundamental
  • Price
  • GMED $60.57
  • GRFS $10.72
  • Analyst Decision
  • GMED Buy
  • GRFS Hold
  • Analyst Count
  • GMED 13
  • GRFS 1
  • Target Price
  • GMED $87.30
  • GRFS $10.30
  • AVG Volume (30 Days)
  • GMED 1.8M
  • GRFS 1.3M
  • Earning Date
  • GMED 08-07-2025
  • GRFS 01-01-0001
  • Dividend Yield
  • GMED N/A
  • GRFS 1.33%
  • EPS Growth
  • GMED 745.36
  • GRFS 132.60
  • EPS
  • GMED 2.57
  • GRFS 0.53
  • Revenue
  • GMED $2,626,461,000.00
  • GRFS $8,744,226,659.00
  • Revenue This Year
  • GMED $15.47
  • GRFS $5.40
  • Revenue Next Year
  • GMED $8.32
  • GRFS $6.74
  • P/E Ratio
  • GMED $23.54
  • GRFS $25.84
  • Revenue Growth
  • GMED 17.43
  • GRFS 9.32
  • 52 Week Low
  • GMED $51.79
  • GRFS $6.19
  • 52 Week High
  • GMED $94.93
  • GRFS $11.14
  • Technical
  • Relative Strength Index (RSI)
  • GMED 60.71
  • GRFS 66.35
  • Support Level
  • GMED $52.68
  • GRFS $10.40
  • Resistance Level
  • GMED $63.11
  • GRFS $10.84
  • Average True Range (ATR)
  • GMED 1.54
  • GRFS 0.32
  • MACD
  • GMED 1.02
  • GRFS -0.04
  • Stochastic Oscillator
  • GMED 77.52
  • GRFS 73.91

About GMED Globus Medical Inc.

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: